beta-Amyloid (1-42), human, HFIP treated, TFA salts

This peptide, HFIP treated, is well suited to the quantitative determination of 42 peptide. Alzheimer’s disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major protein component of these plaques is beta amyloid peptide (A), a 40- to 43- amino-acid peptide cleaved from amyloid precursor protein by secretase (BACE) and a putative (gamma) secretase. Increased release of the ‘longer forms’ of A peptide, A 42 and A 43, which have a greater tendency to aggregate than A 40, occurs in individuals expressing certain genetic mutations, expressing certain ApoE alleles or may other, still undiscovered factors.